Securities code: Betta Pharmaceuticals Co.Ltd(300558) securities abbreviation: Betta Pharmaceuticals Co.Ltd(300558) Announcement No.: 2022030 Betta Pharmaceuticals Co.Ltd(300558)
Announcement on the resolutions of the 24th Meeting of the third board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of supervisors
1. The board of supervisors was convened by Mr. Zhang Yangnan, chairman of the board of supervisors. The meeting notice was sent to all supervisors by e-mail, telephone and other forms on March 21, 2022. The meeting notice of the board of supervisors includes relevant materials of the meeting and lists the time, place, content and method of the meeting.
2. On April 1, 2022, the board of supervisors held an on-site meeting and voted on the spot in the conference room on the third floor of the company's Hangzhou headquarters.
3. The board of supervisors should have 3 people, and the actual number of people attending the meeting is 3.
4. The board of supervisors is presided over by Mr. Zhang Yangnan, chairman of the board of supervisors.
5. The convening, convening and voting procedures of this meeting comply with the company law of the people's Republic of China and other laws and regulations and the relevant provisions of Betta Pharmaceuticals Co.Ltd(300558) articles of association.
2、 Deliberation at the meeting of the board of supervisors
1. Work report of the board of supervisors in 2021
After deliberation, the board of supervisors adopted the work report of the board of supervisors in 2021.
Voting results: 3 in favor, 0 against and 0 abstention. The proposal was passed.
For details of the work report of the board of supervisors in 2021, see the company's disclosure on cninfo.com on the same day（ http://www.cn.info.com.cn. , the same below).
This proposal still needs to be submitted to the 2021 annual general meeting of shareholders for deliberation.
2. Financial statement report of 2021
In 2021, the company achieved an operating revenue of 22458556 million yuan, an increase of 20.08% over the same period of last year; return
The net profit of shareholders of listed companies after deducting non recurring profits and losses was 345680200 yuan, up from the same period of last year
An increase of 3.52%. The supervisors attending the meeting believed that the company's 2021 financial statement objectively and fairly reflected the company's financial situation and operating results in 2021.
Voting results: 3 in favor, 0 against and 0 abstention. The proposal was passed.
The financial statement of 2021 is disclosed on cninfo.com on the same day for details（ http://www.cn.info.com.cn. , the same below).
This proposal still needs to be submitted to the 2021 annual general meeting of shareholders for deliberation.
3. Full text and summary of 2021 Annual Report
After review, the board of supervisors believes that the procedures of the full text and abstract of the company's annual report 2021 prepared and reviewed by the board of directors comply with laws, administrative regulations and the provisions of the CSRC. The contents of the report truly, accurately and completely reflect the company's operation and management in 2021, and there are no false records, misleading statements or major omissions.
Voting results: 3 in favor, 0 against and 0 abstention. The proposal was passed.
The full text of the summary of Betta Pharmaceuticals Co.Ltd(300558) 2021 annual report (Announcement No.: 2022028) was disclosed on cninfo.com on the same day and will be published in the securities times at the same time. The full text of Betta Pharmaceuticals Co.Ltd(300558) 2021 annual report was disclosed on cninfo.com on the same day.
This proposal still needs to be submitted to the 2021 annual general meeting of shareholders for deliberation.
4. 2021 profit distribution plan
The company will distribute cash dividends to all shareholders for every 10 shares based on the total share capital of 415388667 shares
2.50 yuan (including tax), 10384716675 yuan of cash dividend is distributed; The remaining undistributed profits are carried forward and distributed in subsequent years. No conversion of accumulation fund into share capital.
The supervisors attending the meeting held that the profit distribution plan for 2021 proposed by the company is in line with the current development stage of the company
Paragraph matched, taking into account the capital needs of the company's development and the return of investors, and agreed to submit it to the general meeting of shareholders for deliberation. Voting results: 3 in favor, 0 against and 0 abstention. The proposal was passed.
The full text of Betta Pharmaceuticals Co.Ltd(300558) announcement on 2021 annual profit distribution plan (Announcement No.: 2022034) was disclosed on cninfo.com on the same day.
This proposal still needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation.
5. Special report on the use and storage of raised funds in 2021
The board of supervisors carefully reviewed the special report on the use and storage of raised funds in 2021, and believed that the contents of the report truly and accurately reflected the use and balance of raised funds. The company managed the raised funds in strict accordance with the provisions of Betta Pharmaceuticals Co.Ltd(300558) raised funds management system, and there were no violations in the storage, application and supervision of raised funds.
Voting results: 3 in favor, 0 against and 0 abstention. The proposal was passed.
The special report on the use and storage of raised funds in 2021 is detailed in the relevant contents disclosed by the company on cninfo.com on the same day.
6. Self evaluation report on internal control in 2021
After deliberation, the board of supervisors considered that the company's self-evaluation report on internal control in 2021 comprehensively, objectively and truly reflected the actual situation of the establishment, improvement and operation of the company's internal control system. The board of supervisors of the company believes that the company has established a relatively perfect corporate governance structure and internal control system according to its actual situation and the requirements of laws and regulations, and the relevant systems can be effectively implemented. During the reporting period, the company's internal control system was standardized, legal and effective, and there was no violation of the company's internal control system.
Voting results: 3 in favor, 0 against and 0 abstention. The proposal was passed.
For details of the self-evaluation report on internal control in 2021, please refer to the relevant contents disclosed by the company on cninfo.com on the same day.
7. Proposal on reappointment of accounting firm in 2022
Since 2012, Lixin Certified Public Accountants (special general partnership) has provided audit services for the company
Services and audit institutions for the company's initial public offering. Taking into account the continuity of business cooperation, understanding of the company and other factors, in order to ensure the smooth progress of the audit, the board of supervisors agreed to renew the appointment of Lixin Certified Public Accountants (special general partnership) as the audit institution of the company in 2022.
Voting results: 3 in favor, 0 against and 0 abstention. The proposal was passed.
The full text of Betta Pharmaceuticals Co.Ltd(300558) the announcement on renewing the appointment of accounting firms in 2022 (Announcement No.: 2022035) was disclosed on cninfo.com on the same day.
This proposal still needs to be submitted to the 2021 annual general meeting of shareholders for deliberation.
8. Proposal on using idle self owned funds for cash management
After review, the supervisors attending the meeting believed that purchasing principal guaranteed financial products with idle self owned funds was conducive to improving the efficiency of fund use and making rational use of idle self owned funds. The board of supervisors agreed that, without affecting the normal operation of the company, the company could use idle funds with a maximum amount of no more than 1 billion yuan to purchase low-risk, short-term (single transaction no more than 12 months) principal guaranteed financial products (including structured deposits), and the funds could be used in a rolling manner within the above amount. The investment period is from the deliberation and approval of this proposal at the 2021 annual general meeting of shareholders to the convening of the 2022 annual general meeting of shareholders.
Voting results: 3 in favor, 0 against and 0 abstention. The proposal was passed.
The full text of Betta Pharmaceuticals Co.Ltd(300558) announcement on cash management with idle self owned funds (Announcement No.: 2022031) was disclosed on cninfo.com on the same day.
This proposal still needs to be submitted to the 2021 annual general meeting of shareholders for deliberation.
9. Proposal on using idle raised funds for cash management
After review, the supervisors attending the meeting believed that the company's use of idle raised funds for cash management is conducive to further improve the use efficiency of idle raised funds, will not affect the normal progress of the company's investment projects with raised funds, there is no situation of changing the purpose of raised funds in a disguised form, and there is no situation of damaging the interests of the company and all shareholders, especially small and medium-sized shareholders. The board of supervisors agreed that the company should use the idle raised funds with a maximum amount of no more than 400 million yuan to purchase short-term (no more than 12 months) principal guaranteed bank financial products (excluding the venture capital varieties involved in the guidelines for the standardized operation of companies listed on the gem of Shenzhen Stock Exchange). The investment period is from the deliberation and approval of this proposal at the 2021 annual general meeting to the convening of the 2022 annual general meeting, Within the above quota and service life, the funds can be used on a rolling basis.
Voting results: 3 in favor, 0 against and 0 abstention. The proposal was passed.
The full text of Betta Pharmaceuticals Co.Ltd(300558) announcement on cash management with idle raised funds (Announcement No.: 2022032) was disclosed on cninfo.com on the same day.
This proposal still needs to be submitted to the 2021 annual general meeting of shareholders for deliberation.
3、 Documents for future reference
1. Betta Pharmaceuticals Co.Ltd(300558) the resolution of the 24th Meeting of the third board of supervisors.
It is hereby announced.
Betta Pharmaceuticals Co.Ltd(300558) board of supervisors April 6, 2022
